恩瑞格国内上市没？

(deferasirox, Exjade, DFX) is easy to take, has good safety and tolerability, good treatment compliance, accurate iron removal effect, and can effectively improve patients' iron overload condition. So has Deferasirox been launched in the country?

In 2005, Deferasirox was approved by the FDA for the treatment of chronic iron overload caused by blood transfusion. The original drug was developed by Novartis. In January 2013, the FDA approved expanded indications to treat chronic iron overdose caused by Non-Transfusion Dependent Thalassemia Syndromes (NTDT), making Exjade the first drug to treat this indication. NTDT is a mild form of thalassemia that does not require frequent blood transfusions. However, even if patients do not receive blood transfusions, they will accumulate excess iron and damage various tissues and organs. Currently, Deferasirox has been approved in more than 100 countries around the world for the treatment of transfusion-induced iron overload in children over 2 years old. In China, only the original deferasirox dispersible tablets (trade name: Enrig) ​​from Novartis Pharmaceuticals were launched in June 2010, and only Jiangsu Aosaikang Pharmaceutical is applying for a domestic generic version.

The recommended starting daily dose of Deferasirox is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered. In patients who have already responded well to deferoxamine therapy, an initial dose of Deferasirox equivalent to half the deferoxamine dose may be considered. (For example, a patient receiving deferoxamine 40 mg/kg/day, 5 days per week, or equivalent, may start at 20 mg/kg if switched to Deferasirox.)

How to take: (Deferasirox) should be taken on an empty stomach at least 30 minutes before a meal, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Deferasirox should not be taken with aluminum-containing antacids, and the dose (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before taking. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.